US20040242567A1 - Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension - Google Patents
Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension Download PDFInfo
- Publication number
- US20040242567A1 US20040242567A1 US10/492,804 US49280404A US2004242567A1 US 20040242567 A1 US20040242567 A1 US 20040242567A1 US 49280404 A US49280404 A US 49280404A US 2004242567 A1 US2004242567 A1 US 2004242567A1
- Authority
- US
- United States
- Prior art keywords
- irbesartan
- preventing
- hypertension
- treating pulmonary
- pulmonary hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a novel use of irbesartan for the preparation of medicinal products that are useful for preparing medicinal products for preventing or treating pulmonary hypertension or pulmonary arterial hypertension.
- Irbesartan is an antagonist of the angiotensin II AT 1 receptors.
- Irbesartan alone or in combination with a diuretic agent, is indicated in the treatment of various cardiovascular complaints, especially hypertension and diabetic nephropathy.
- Pulmonary arterial hypertension or pulmonary hypertension corresponds to an increase in pressure in the pulmonary arterial network to above 35 mmHg; the vital prognosis of this disease is dramatic.
- the caliber of the pulmonary arterials and vessels shrinks and the resulting pressure increase has repercussions on the right ventricle; right ventricular insufficiency is gradually manifested and gets worse.
- one subject of the present invention is the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension or pulmonary arterial hypertension.
- irbesartan may also be used in combination with another active principle, for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension, for example a diuretic agent such as hydrochlorothiazide, an aquaretic agent, such as a vasopressin V 2 receptor antagonist, a vasodilator, an anticoagulant, a phosphodiesterase inhibitor, prostacyclin or an endothelin receptor antagonist such as bosentan.
- a diuretic agent such as hydrochlorothiazide
- an aquaretic agent such as a vasopressin V 2 receptor antagonist, a vasodilator, an anticoagulant, a phosphodiesterase inhibitor, prostacyclin or an endothelin receptor antagonist such as bosentan.
- irbesartan For its use as a medicinal product, irbesartan, a pharmaceutically acceptable salt thereof or a solvate thereof, alone or in combination with another active principle, should be formulated as a pharmaceutical composition.
- the active principle in the pharmaceutical compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, may be administered in unit administration form, as a mixture with standard pharmaceutical supports, to animals and human beings.
- the appropriate unit administration forms comprise oral forms such as tablets, gel capsules, pills, powders, granules and oral solutions or-suspensions, sublingual and buccal administration forms, aerosols, topical administration forms, implants, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal administration forms.
- the active principle(s) is(are) generally formulated in dosage units.
- the dosage unit contains 50 to 500 mg and-advantageously from 75 to 300 mg of active principle per dosage unit, for daily administrations, one or more times a day.
- a treatment by inhalation may also be chosen; in this case, the inhaled doses are smaller.
- the dosage that is appropriate for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
- a mixture of pharmaceutical excipients is added to the active principles, which may or may not be micronized, this mixture possibly being composed of diluents, for instance lactose, mannitol, microcrystalline cellulose, starch or dicalcium phosphate, binders, for instance polyvinylpyrrolidone or hydroxypropylmethylcellulose, disintegrating agents such as crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose or sodium croscarmellose, glidants, for instance silica or talc, and lubricants, for instance magnesium stearate, stearic acid, glyceryl tribehenate or sodium stearylfumarate.
- diluents for instance lactose, mannitol, microcrystalline cellulose, starch or dicalcium phosphate
- binders for instance polyvinylpyrrolidone or hydroxypropylmethylcellulose
- disintegrating agents such as crosslinked polyvinylpyrrolidone
- wetting agents or surfactants such as sodium lauryl sulfate, polysorbate 80 or poloxamer 188 may be added to the formulation.
- the tablets may be made via various techniques: direct compression, dry granulation, wet granulation or hot-melting.
- the tablets may be plain or sugar-coated (for example with sucrose) or coated with various polymers or other suitable materials.
- the tablets may have a flash, delayed or sustained release by making polymer matrices or by using specific polymers in the film coating.
- the gel capsules may be soft or hard, and uncoated or film-coated so as to have flash, sustained or delayed activity (for example via a gastroresistant form). They may contain not only a solid formulation formulated as above for the tablets, but also liquids or semisolids.
- a preparation in syrup or elixir form may contain the active principle(s) together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavor enhancer and a suitable dye.
- a sweetener preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavor enhancer and a suitable dye.
- the water-dispersible powders or granules may contain the active principle(s) as a mixture with dispersants or wetting agents, or suspension agents, for instance polyvinylpyrrolidone or polyvidone, and also with sweeteners or flavor enhancers.
- suppositories which are prepared with binders that melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
- aqueous suspensions for example isotonic saline solutions or sterile injectable solutions containing pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or butylene glycol, are used.
- pharmacologically compatible dispersants and/or solubilizing agents for example propylene glycol or butylene glycol
- a cosolvent for example an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as polysorbate 80 or poloxamer 188.
- the active principle may be dissolved with a triglyceride or a glycerol ester.
- Creams, ointments, gels, eye drops or sprays may be used for local administration.
- Patches in multilaminar or reservoir form in which the active principle is in alcoholic solution may be used for transdermal administration.
- An aerosol containing, for example, sorbitan trioleate or oleic acid and also trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane, freon substitutes or any other biologically compatible propellent gas is used for administration by inhalation; a system containing the active principle alone or combined-with an excipient, in powder form, may also be used.
- the active principle(s) may also be in the form of a complex with a cyclodextrin, for example ⁇ -, ⁇ - or ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin or methyl- ⁇ -cyclodextrin.
- a cyclodextrin for example ⁇ -, ⁇ - or ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin or methyl- ⁇ -cyclodextrin.
- the active principle(s) may also be formulated in the form of microcapsules or microspheres, optionally with one or more supports or additives.
- sustained-release forms that are useful in the case of chronic treatments, use may be made of implants. These may be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
- the irbesartan is administered orally, as a single dosage intake per day or by inhalation using an aerosol, one or more times a day.
- the invention also relates to a method that consists in administering a therapeutically effective amount of irbesartan, a pharmaceutically acceptable salt thereof or a solvate thereof.
- MCT monocrotaline
- the treatment with irbesartan was started either 21 days or 14 days after injection of monocrotaline. Irbesartan was incorporated into the food in powder form. The control animals received food alone.
- irbesartan was administered alone at a dose of 50 mg/kg.
- irbesartan was administered alone at a dose of 30 mg/kg and in combination with hydrochlorothiazide (HCTZ): irbesartan: 30 mg/kg and HCTZ: 10 mg/kg.
- HCTZ hydrochlorothiazide
- Irbesartan administered at a dose of 50 mg/kg/day, either from the 21st day or from the 14th day post-MCT, significantly increased the survival time of the MCT-treated rats.
- Study 2 Survival to the end Survival to the of the study (85th Groups 50th day day) Controls 16.7% (4/24) 4.2% (1/24) Irbesartan 47.8% (11/23) 0% (0/23) 30 mg/kg HCTZ 25% (6/24) 4.2% (1/24) 10 mg/kg Irbesartan 30 mg/kg 60.9% (14/23) 39.1% (9/23) HCTZ 10 mg/kg
- EXAMPLE 1 EXAMPLE 2
- EXAMPLE 3 Irbesartan 75.00 mg 150.00 mg 300.00 mg Lactose monohydrate 15.38 mg 30.75 mg 61.50 mg Microcrystalline 19.50 mg 39.00 mg 78.00 mg cellulose Pregelatinized 22.50 mg 45.00 mg 90.00 mg corn starch Sodium croscarmellose 7.50 mg 15.00 mg 30.00 mg Poloxamer 188 4.50 mg 9.00 mg 18.00 mg Hydrated colloidal 4.12 mg 8.25 mg 16.50 mg silica Magnesium stearate 1.50 mg 3.00 mg 6.00 mg Purified water qs qs qs 150.00 mg 300.00 mg 600.00 mg
- EXAMPLE 4 EXAMPLE 5 Irbesartan 150.00 mg 300.00 mg Hydrochlorothiazide 12.50 mg 12.50 mg Lactose monohydrate 26.65 mg 65.80 mg Microcrystalline cellulose 45.00 mg 90.00 mg Pregelatinized corn starch 45.00 mg 90.00 mg Sodium croscarmellose 15.00 mg 30.00 mg Red iron oxide 0.30 mg 0.60 mg Yellow iron oxide 0.30 mg 0.60 mg Hydrated colloidal silica 2.25 mg 4.50 mg Magnesium stearate 3.00 mg 6.00 mg Purified water qs qs 300.00 mg 600.00 mg 600.00 mg
Abstract
Description
- The present invention relates to a novel use of irbesartan for the preparation of medicinal products that are useful for preparing medicinal products for preventing or treating pulmonary hypertension or pulmonary arterial hypertension.
- Irbesartan is an antagonist of the angiotensin II AT1 receptors.
- This compound and its mode of preparation are described in patents EP 454,511 and U.S. Pat. No. 5,270,317.
- Irbesartan, alone or in combination with a diuretic agent, is indicated in the treatment of various cardiovascular complaints, especially hypertension and diabetic nephropathy.
- Pulmonary arterial hypertension or pulmonary hypertension corresponds to an increase in pressure in the pulmonary arterial network to above 35 mmHg; the vital prognosis of this disease is dramatic. During this disease, the caliber of the pulmonary arterials and vessels shrinks and the resulting pressure increase has repercussions on the right ventricle; right ventricular insufficiency is gradually manifested and gets worse.
- The effect of losartan, an antagonist of the angiotensin II AT1 receptors, was tested in this disease using an animal model in which the pulmonary hypertension is induced with monocrotaline. Monocrotaline (MCT) is an alkaloid toxin that induces pulmonary vascular impairments leading to the development of pulmonary hypertension, which is the cause of a right ventricular hypertrophy. This evolutive pathology is reflected by a near-total death of the animals within a few weeks. At the terminal stage, the presence of pulmonary edema is noted.
- In this model it was found by two different groups of authors that losartan has no effect:
- L. Cassis et al.: J. Pharmacol. Exp. Therap. 1992, 262(3), 1168-1172 and Biochem. Pharmacol., 1997, 54(1), 27-31,
- R. Kreutz et al.: Clin. Exp. Hypertens., 1996, 18(1), 101-111.
- It has now been found, surprisingly, that irbesartan is, itself, active on this model of arterial hypertension.
- Thus, one subject of the present invention is the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension or pulmonary arterial hypertension.
- According to the present invention, irbesartan may also be used in combination with another active principle, for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension, for example a diuretic agent such as hydrochlorothiazide, an aquaretic agent, such as a vasopressin V2 receptor antagonist, a vasodilator, an anticoagulant, a phosphodiesterase inhibitor, prostacyclin or an endothelin receptor antagonist such as bosentan.
- For its use as a medicinal product, irbesartan, a pharmaceutically acceptable salt thereof or a solvate thereof, alone or in combination with another active principle, should be formulated as a pharmaceutical composition.
- In the pharmaceutical compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, may be administered in unit administration form, as a mixture with standard pharmaceutical supports, to animals and human beings. The appropriate unit administration forms comprise oral forms such as tablets, gel capsules, pills, powders, granules and oral solutions or-suspensions, sublingual and buccal administration forms, aerosols, topical administration forms, implants, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal administration forms.
- In the pharmaceutical compositions of the present invention, the active principle(s) is(are) generally formulated in dosage units. The dosage unit contains 50 to 500 mg and-advantageously from 75 to 300 mg of active principle per dosage unit, for daily administrations, one or more times a day.
- For the treatment of pulmonary hypertension, according to the present invention, a treatment by inhalation may also be chosen; in this case, the inhaled doses are smaller.
- Although these doses are examples of average situations, there may be particular cases in which higher or lower doses are appropriate, and such doses also form part of the invention. According to the usual practice, the dosage that is appropriate for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
- When a solid composition in the form of tablets or gel capsules is prepared, a mixture of pharmaceutical excipients is added to the active principles, which may or may not be micronized, this mixture possibly being composed of diluents, for instance lactose, mannitol, microcrystalline cellulose, starch or dicalcium phosphate, binders, for instance polyvinylpyrrolidone or hydroxypropylmethylcellulose, disintegrating agents such as crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose or sodium croscarmellose, glidants, for instance silica or talc, and lubricants, for instance magnesium stearate, stearic acid, glyceryl tribehenate or sodium stearylfumarate.
- Wetting agents or surfactants such as sodium lauryl sulfate, polysorbate 80 or poloxamer 188 may be added to the formulation.
- The tablets may be made via various techniques: direct compression, dry granulation, wet granulation or hot-melting.
- The tablets may be plain or sugar-coated (for example with sucrose) or coated with various polymers or other suitable materials.
- The tablets may have a flash, delayed or sustained release by making polymer matrices or by using specific polymers in the film coating.
- The gel capsules may be soft or hard, and uncoated or film-coated so as to have flash, sustained or delayed activity (for example via a gastroresistant form). They may contain not only a solid formulation formulated as above for the tablets, but also liquids or semisolids.
- A preparation in syrup or elixir form may contain the active principle(s) together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavor enhancer and a suitable dye.
- The water-dispersible powders or granules may contain the active principle(s) as a mixture with dispersants or wetting agents, or suspension agents, for instance polyvinylpyrrolidone or polyvidone, and also with sweeteners or flavor enhancers.
- For rectal administration, use is made of suppositories, which are prepared with binders that melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
- For parenteral, intranasal or intraocular administration, aqueous suspensions, isotonic saline solutions or sterile injectable solutions containing pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or butylene glycol, are used.
- Thus, to prepare an aqueous solution for intravenous injection, it is possible to use a cosolvent, for example an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as polysorbate 80 or poloxamer 188. To prepare an oily solution for intramuscular injection, the active principle may be dissolved with a triglyceride or a glycerol ester.
- Creams, ointments, gels, eye drops or sprays may be used for local administration.
- Patches in multilaminar or reservoir form in which the active principle is in alcoholic solution may be used for transdermal administration.
- An aerosol containing, for example, sorbitan trioleate or oleic acid and also trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane, freon substitutes or any other biologically compatible propellent gas is used for administration by inhalation; a system containing the active principle alone or combined-with an excipient, in powder form, may also be used.
- The active principle(s) may also be in the form of a complex with a cyclodextrin, for example α-, β- or γ-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin or methyl-β-cyclodextrin.
- The active principle(s) may also be formulated in the form of microcapsules or microspheres, optionally with one or more supports or additives.
- Among the sustained-release forms that are useful in the case of chronic treatments, use may be made of implants. These may be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
- Preferably, the irbesartan is administered orally, as a single dosage intake per day or by inhalation using an aerosol, one or more times a day.
- According to another of its aspects, the invention also relates to a method that consists in administering a therapeutically effective amount of irbesartan, a pharmaceutically acceptable salt thereof or a solvate thereof.
- Male Sprague-Dawley rats weighing about 300 g received a subcutaneous injection of monocrotaline (MCT) at a dose of 80 mg/kg.
- The treatment with irbesartan was started either 21 days or 14 days after injection of monocrotaline. Irbesartan was incorporated into the food in powder form. The control animals received food alone.
- Throughout the study, the animals were examined daily.
- In a first study, irbesartan was administered alone at a dose of 50 mg/kg. In a second study, irbesartan was administered alone at a dose of 30 mg/kg and in combination with hydrochlorothiazide (HCTZ): irbesartan: 30 mg/kg and HCTZ: 10 mg/kg.
- Study 1:
Survival to the Survival to Survival to end of the study Groups the 25th day the 50th day (57th day) Controls 100% (18/18) 33% (6/18) 17% (3/18) Irbesartan 100% (18/18) 72% (13/18) 61% (11/18) 50 mg/kg — p = 0.043 p = 0.015 -
Survival to the Survival to Survival to end of the study Groups the 25th day the 50th day (100th day) Controls 100% (12/12) 33% (4/12) 0% (0/12) Irbesartan 100% (12/12) 83% (10/12) 50% (6/12) 50 mg/kg — p = 0.036 p = 0.014 - Irbesartan, administered at a dose of 50 mg/kg/day, either from the 21st day or from the 14th day post-MCT, significantly increased the survival time of the MCT-treated rats.
- When the treatment was started on the 21st day, it was observed at the end of the study that 17% of the control animals were still alive, versus 61% of the irbesartan-treated animals (p=0.0153, Fisher test). Furthermore, in the treated group, a significant increase is seen in the survival time from the 35th day relative to the control group (p=0.0160, log-rank test).
- When the treatment was started on the 14th day, at the end of the study, whereas all the control animals were dead, 50% of the irbesartan-treated animals were still alive (p=0.014, Fisher test). Furthermore, a significant increase is seen in the overall survival time estimated in the treated group (>93 days) compared with the control group (46 days) (p=0.0001, log-rank test).
- Study 2:
Survival to the end Survival to the of the study (85th Groups 50th day day) Controls 16.7% (4/24) 4.2% (1/24) Irbesartan 47.8% (11/23) 0% (0/23) 30 mg/kg HCTZ 25% (6/24) 4.2% (1/24) 10 mg/kg Irbesartan 30 mg/kg 60.9% (14/23) 39.1% (9/23) HCTZ 10 mg/kg - This study, performed at a lower dose of irbesartan than the first study, demonstrates an increase in the survival time at the end of the study for the animals treated with the irbesartan+HCTZ combination, compared with irbesartan alone (p=Q.0015, Fisher test). The median estimated survival time is 70 days for the animals treated with the combination, versus 46 days for the animals treated with irbesartan alone (p=0.0033, log-rank test).
- This set of results demonstrates a beneficial effect of irbesartan on mortality consecutive to pulmonary hypertension induced by injection of monocrotaline in rats. This beneficial effect is potentiated when the irbesartan is coadministered with a diuretic agent such as hydrochlorothiazide.
-
EXAMPLE 1 EXAMPLE 2 EXAMPLE 3 Irbesartan 75.00 mg 150.00 mg 300.00 mg Lactose monohydrate 15.38 mg 30.75 mg 61.50 mg Microcrystalline 19.50 mg 39.00 mg 78.00 mg cellulose Pregelatinized 22.50 mg 45.00 mg 90.00 mg corn starch Sodium croscarmellose 7.50 mg 15.00 mg 30.00 mg Poloxamer 188 4.50 mg 9.00 mg 18.00 mg Hydrated colloidal 4.12 mg 8.25 mg 16.50 mg silica Magnesium stearate 1.50 mg 3.00 mg 6.00 mg Purified water qs qs qs 150.00 mg 300.00 mg 600.00 mg -
EXAMPLE 4 EXAMPLE 5 Irbesartan 150.00 mg 300.00 mg Hydrochlorothiazide 12.50 mg 12.50 mg Lactose monohydrate 26.65 mg 65.80 mg Microcrystalline cellulose 45.00 mg 90.00 mg Pregelatinized corn starch 45.00 mg 90.00 mg Sodium croscarmellose 15.00 mg 30.00 mg Red iron oxide 0.30 mg 0.60 mg Yellow iron oxide 0.30 mg 0.60 mg Hydrated colloidal silica 2.25 mg 4.50 mg Magnesium stearate 3.00 mg 6.00 mg Purified water qs qs 300.00 mg 600.00 mg -
Micronized irbesartan 4 mg Lactose qs 20 mg - For a powder inhalation drvice, composed of 7 disks of 8 doses, each weighing 20 mg.
-
Micronized irbesartan 1 mg Lactose qs 6 mg - For a powder inhalation device, containing a cartridge of 12 alveolae, each containing 4 mg of formulation.
-
Micronized irbesartan 4 mg Lactose 50 microns qs 20 mg - For a finished size 3 gel capsule weighing 20 mg. Box of 30 gel capsules. Powder inhalation device.
-
Micronized irbesartan 600 mg Freon 12 14 g - For a pressurized flask with a metering valve, containing 150 doses.
-
Micronized irbesartan 600 mg Freon 11 4.7 g Freon 12 9.8 g - For a pressurized flask with a metering valve, containing 150 doses.
-
Micronized irbesartan 300 mg HFA (hydrofluoroalkane) 134a 13 g Sorbitan trioleate 30 mg - For a pressurized flask with a metering valve, containing 150 doses.
-
Micronized irbesartan 300 mg Freon 11 4.7 g Freon 12 9.8 g Oleic acid 40 mg - For a pressurized flask with a metering valve, containing 150 doses.
-
Micronized irbesartan 600 mg HCTZ 25 mg Freon 12 14 g - For a pressurized flask with a metering valve, containing 150 doses.
-
Micronized irbesartan 300 mg HCTZ 25 mg HFA (hydrofluoroalkane) 13 g Sorbitan trioleate 30 mg - For a pressurized flask with a metering valve, containing 150 doses.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/477,562 US8088827B2 (en) | 2001-10-26 | 2009-06-03 | Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/13936 | 2001-10-26 | ||
FR0113936A FR2831446B1 (en) | 2001-10-26 | 2001-10-26 | USE OF IRBESARTAN FOR THE PREPARATION OF MEDICINES USEFUL FOR THE PREVENTION OR TREATMENT OF PULMONARY HYPERTENSION |
PCT/FR2002/003439 WO2003035062A1 (en) | 2001-10-26 | 2002-10-09 | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/477,562 Continuation US8088827B2 (en) | 2001-10-26 | 2009-06-03 | Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040242567A1 true US20040242567A1 (en) | 2004-12-02 |
Family
ID=8868812
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/492,804 Abandoned US20040242567A1 (en) | 2001-10-26 | 2002-10-09 | Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension |
US12/477,562 Expired - Fee Related US8088827B2 (en) | 2001-10-26 | 2009-06-03 | Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/477,562 Expired - Fee Related US8088827B2 (en) | 2001-10-26 | 2009-06-03 | Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |
Country Status (24)
Country | Link |
---|---|
US (2) | US20040242567A1 (en) |
EP (1) | EP1441723B1 (en) |
JP (1) | JP4542777B2 (en) |
CN (1) | CN100418526C (en) |
AT (1) | ATE361071T1 (en) |
AU (1) | AU2002350832B2 (en) |
BR (1) | BR0213479A (en) |
CA (1) | CA2461625C (en) |
CY (1) | CY1106746T1 (en) |
DE (1) | DE60219940T2 (en) |
DK (1) | DK1441723T3 (en) |
EA (1) | EA007952B1 (en) |
ES (1) | ES2286304T3 (en) |
FR (1) | FR2831446B1 (en) |
HU (1) | HUP0401633A3 (en) |
IL (2) | IL161116A0 (en) |
IS (1) | IS2849B (en) |
MX (1) | MXPA04003910A (en) |
NO (1) | NO332313B1 (en) |
NZ (1) | NZ532130A (en) |
PL (1) | PL209263B1 (en) |
PT (1) | PT1441723E (en) |
WO (1) | WO2003035062A1 (en) |
ZA (1) | ZA200402696B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060104913A1 (en) * | 2003-06-27 | 2006-05-18 | Merck Patent Gmbh | Inhalable formulations for treating pulmonary hypertension and methods of using same |
WO2006067601A1 (en) * | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation |
WO2008026012A1 (en) * | 2006-08-31 | 2008-03-06 | Generics [Uk] Limited | Novel compositions and methods |
WO2022198264A1 (en) * | 2021-03-23 | 2022-09-29 | Dimerix Bioscience Pty Ltd | Treatment of inflammatory diseases |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
TR200301553A1 (en) * | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | New oral pharmaceutical formulations containing irbesartan active ingredient |
US8226977B2 (en) | 2004-06-04 | 2012-07-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
CN100367959C (en) * | 2006-08-29 | 2008-02-13 | 陈俊云 | Medicine contg. irbesartan |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5292741A (en) * | 1992-08-18 | 1994-03-08 | Merck & Co., Inc. | Macrocycles incorporating quinazolinones |
US5292740A (en) * | 1991-06-13 | 1994-03-08 | Hoffmann-La Roche Inc. | Sulfonamides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT97078B (en) * | 1990-03-20 | 1997-07-31 | Sanofi Sa | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US20020068740A1 (en) | 1999-12-07 | 2002-06-06 | Mylari Banavara L. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
-
2001
- 2001-10-26 FR FR0113936A patent/FR2831446B1/en not_active Expired - Fee Related
-
2002
- 2002-10-09 DE DE60219940T patent/DE60219940T2/en not_active Expired - Lifetime
- 2002-10-09 EP EP02785535A patent/EP1441723B1/en not_active Expired - Lifetime
- 2002-10-09 JP JP2003537629A patent/JP4542777B2/en not_active Expired - Fee Related
- 2002-10-09 PL PL368737A patent/PL209263B1/en unknown
- 2002-10-09 HU HU0401633A patent/HUP0401633A3/en unknown
- 2002-10-09 CA CA2461625A patent/CA2461625C/en not_active Expired - Fee Related
- 2002-10-09 EA EA200400438A patent/EA007952B1/en not_active IP Right Cessation
- 2002-10-09 MX MXPA04003910A patent/MXPA04003910A/en active IP Right Grant
- 2002-10-09 ES ES02785535T patent/ES2286304T3/en not_active Expired - Lifetime
- 2002-10-09 WO PCT/FR2002/003439 patent/WO2003035062A1/en active IP Right Grant
- 2002-10-09 CN CNB028213041A patent/CN100418526C/en not_active Expired - Fee Related
- 2002-10-09 AT AT02785535T patent/ATE361071T1/en active
- 2002-10-09 NZ NZ532130A patent/NZ532130A/en not_active IP Right Cessation
- 2002-10-09 US US10/492,804 patent/US20040242567A1/en not_active Abandoned
- 2002-10-09 PT PT02785535T patent/PT1441723E/en unknown
- 2002-10-09 DK DK02785535T patent/DK1441723T3/en active
- 2002-10-09 IL IL16111602A patent/IL161116A0/en unknown
- 2002-10-09 BR BR0213479-9A patent/BR0213479A/en not_active Application Discontinuation
- 2002-10-09 AU AU2002350832A patent/AU2002350832B2/en not_active Ceased
-
2004
- 2004-03-25 IL IL161116A patent/IL161116A/en not_active IP Right Cessation
- 2004-03-29 IS IS7200A patent/IS2849B/en unknown
- 2004-04-06 ZA ZA2004/02696A patent/ZA200402696B/en unknown
- 2004-04-23 NO NO20041732A patent/NO332313B1/en not_active IP Right Cessation
-
2007
- 2007-07-19 CY CY20071100964T patent/CY1106746T1/en unknown
-
2009
- 2009-06-03 US US12/477,562 patent/US8088827B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5292740A (en) * | 1991-06-13 | 1994-03-08 | Hoffmann-La Roche Inc. | Sulfonamides |
US5292741A (en) * | 1992-08-18 | 1994-03-08 | Merck & Co., Inc. | Macrocycles incorporating quinazolinones |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060104913A1 (en) * | 2003-06-27 | 2006-05-18 | Merck Patent Gmbh | Inhalable formulations for treating pulmonary hypertension and methods of using same |
US9498437B2 (en) | 2003-06-27 | 2016-11-22 | Mylan Specialty L.P. | Inhalable formulations for treating pulmonary hypertension and methods of using same |
WO2006067601A1 (en) * | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation |
WO2008026012A1 (en) * | 2006-08-31 | 2008-03-06 | Generics [Uk] Limited | Novel compositions and methods |
US20090312380A1 (en) * | 2006-08-31 | 2009-12-17 | Axel Becker | Novel compositions and methods |
WO2022198264A1 (en) * | 2021-03-23 | 2022-09-29 | Dimerix Bioscience Pty Ltd | Treatment of inflammatory diseases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088827B2 (en) | Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension | |
AU781827B2 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
RU2423975C2 (en) | Solid medication of olmesartan medoxomil and amlodipine | |
KR20080076961A (en) | Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist | |
JPH11228410A (en) | Chronic renal insufficiency therapeutic agent comprising imidazole angiotensin-ii receptor antagonist | |
US20230201174A1 (en) | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases | |
AU764304B2 (en) | Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders | |
MXPA06011823A (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor. | |
US20170157095A1 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition | |
US10016397B2 (en) | Selective AT2 receptor agonists for use in treatment of cachexia | |
JP2006518765A (en) | Method of treating disease using an adenosine A1 receptor antagonist | |
RU2182002C2 (en) | Composition containing fixed dose of angiotensin-transforming enzyme and calcium canal antagonist and method for producing the composition and treating cardiovascular diseases | |
SG190326A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
KR20050100676A (en) | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention | |
US20100249103A1 (en) | combination treatment | |
KR20070084315A (en) | Methods of using pde v inhibitors for the treatment of congestive heart failure | |
EP1115399B1 (en) | Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii at 1? receptors and indomethacin for making a medicine treating chronic glomerulonephritis | |
EP0310259B1 (en) | Eperisone as a hypotensive agent | |
WO2004091659A1 (en) | Drug for preventing or treating angiogenic eye diseases | |
WO2011027021A1 (en) | A method for the treatment of hypertension | |
JPWO2019111829A1 (en) | A prophylactic or therapeutic agent for pulmonary hypertension containing mebendazole and / or itraconazole or a salt thereof. | |
KR20050086820A (en) | Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor | |
JP2000290198A (en) | Depressant against nasal cavity resistant increase or the like |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-SYNTHELABO, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COSNIER-PUCHEU, SYLVIE;NISATO, DINO;ROCCON, ALAIN;REEL/FRAME:015638/0938 Effective date: 20040309 |
|
AS | Assignment |
Owner name: SANOFI-AVENTIS,FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-SYNTHELABO;REEL/FRAME:016345/0189 Effective date: 20040820 Owner name: SANOFI-AVENTIS, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-SYNTHELABO;REEL/FRAME:016345/0189 Effective date: 20040820 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |